Miltenyi Biotec
Miltenyi Biotec is a privately held German biotechnology company that designs, manufactures, and integrates cell and gene therapy tools, reagents, and automated manufacturing systems, serving pharmaceutical, biotech, academic, and hospital customers globally.
- Company typePrivate
- Founded1989
- HeadquartersBergisch Gladbach, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Miltenyi Biotec does
Miltenyi Biotec is a privately held German biotechnology company founded in 1989 and headquartered in Bergisch Gladbach, with 1,001-5,000 employees and operations across Europe and South Asia. The company designs, develops, manufactures, and integrates products that support biomedical research and enable cell and gene therapy, and is identified as a top-5 player in the global cell and gene therapy tools and reagents market alongside Thermo Fisher Scientific, Cytiva (Danaher), Merck KGaA, and Sartorius.
Its core product portfolio centers on the CliniMACS Prodigy, an automated, closed-system manufacturing platform for therapeutic cells, combined with proprietary magnetic-activated cell sorting (MACS) reagents and consumables for cell enrichment (e.g., CD34+ stem cells, NK cells from umbilical cord blood). The company acquired Lino Biotech in February 2023 to add a biosensor platform for molecular interaction measurement, extending its offering into quality control and bioprocess monitoring. It is also developing ZAMTO Cell, a dual-target CAR-T cancer therapy targeted for 2026 availability in India, signaling a move from purely enabling tools into therapeutic product development. Additional acquisitions across its history (LaVision BioTec, Sensovation AG, Lentigen, Owl biomedical, Eligix) have built a vertically integrated instruments, reagents, and vectors portfolio.
Miltenyi Biotec generates revenue primarily through the sale of cell and gene therapy tools, reagents, and consumables, alongside the sale and service of automated manufacturing systems such as the CliniMACS Prodigy. Pricing is not publicly disclosed; the company sells through a direct enterprise field sales motion to pharmaceutical companies, biotech firms, academic and clinical research organizations, and hospitals, supplemented by event-driven marketing and reference sites such as the Hyderabad Cell and Gene Therapy Center of Excellence opened in February 2025. Leadership includes Founder, Managing Director, President, and CEO Stefan Miltenyi, CFO and Managing Director Norbert Henschel, and President of North America Markus Weiss.
Miltenyi Biotec firmographics
Firmographics- Name
- Miltenyi Biotec
- Legal name
- Miltenyi Biotec
- Website
- https://miltenyibiotec.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Miltenyi Biotec is a privately held German biotechnology company that designs, manufactures, and integrates cell and gene therapy tools, reagents, and automated manufacturing systems, serving pharmaceutical, biotech, academic, and hospital customers globally.
- Ownership category
- akta.pro rank
Miltenyi Biotec industry classification
Industry- Product category
- Cell and Gene Therapy Manufacturing Technologies
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI)
Keywords
Where Miltenyi Biotec is headquartered
LocationHeadquarters
- HQ city
- Bergisch Gladbach
- HQ country
- Germany
- HQ region
- Europe
Offices3 records
Markets served
Miltenyi Biotec business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Cell and Gene Therapy Tools and Reagents: Sale of reagents, consumables, and tools for cell and gene therapy development and manufacturing including magnetic cell separation reagents, culture media, and biosensors.
- Automated Cell Therapy Processing Systems: Sale and service of automated manufacturing systems (CliniMACS Prodigy) for closed-system cell therapy processing used in clinical and commercial manufacturing.
- Cell Therapy Technologies: Comprehensive cell therapy technology solutions including instruments, reagents, and consumables for personalized and regenerative medicine applications.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Miltenyi Biotec product offering
Product offeringCore offering
Miltenyi Biotec designs, develops, manufactures, and integrates products that empower biomedical research and enable cell and gene therapy. The company sells automated closed-system cell therapy processing platforms (e.g., CliniMACS Prodigy), magnetic cell separation reagents and instruments, molecular interaction biosensors (via Lino Biotech), and a comprehensive portfolio of tools and reagents used in research, clinical, and commercial cell therapy manufacturing.
Product overview
Miltenyi Biotec offers a unified portfolio centered on cell and gene therapy solutions. The core offerings include the CliniMACS Prodigy automated manufacturing system, the ZAMTO Cell dual-target CAR-T therapy (in development), and the Lino Biotech biosensor platform (acquired in 2023). These products are complemented by a comprehensive range of tools and reagents for cell and gene therapy development, manufacturing, and quality control. The company operates India\'s first Cell and Gene Therapy Center of Excellence in Hyderabad.
Differentiator
Problem solved
Functional benefit
Products and services
- CliniMACS Prodigy Automated, closed-system manufacturing platform for therapeutic cells including NK cells and CD34+ stem cell enrichment, used by clinical and commercial cell therapy manufacturers for scalable, GMP-compliant production.
- ZAMTO Cell Dual-target CAR-T cancer therapy product developed by Miltenyi Biotec India, intended for oncology treatment.
- Lino Biotech Biosensor Platform Biosensor technology for molecular interaction measurement, integrated with Miltenyi's cell and gene therapy approaches to enhance quality control and reduce costs in bioprocessing and drug discovery.
- Cell and Gene Therapy Tools and Reagents Comprehensive portfolio of magnetic cell separation reagents, culture media, instruments, consumables, and related tools supporting cell and gene therapy development, manufacturing, and quality control.
Quantifiable outcome
- Automated NK cell manufacturing demonstrates consistent efficiency in CD34+ stem cell enrichment regardless of initial cell content or sample age
- +1 more outcomes
Companies that use Miltenyi Biotec
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Miltenyi Biotec technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Miltenyi Biotec partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor, major, strategic and core.
- BioAsia 2026minorActive participation at BioAsia 2026 conference in Hyderabad with executives featured as keynote speakers and panel participants discussing TechBio innovation and the future of life sciences.
- BIRACmajorMiltenyi Biotec India and BIRAC (Biotechnology Industry Research Assistance Council) signed a Letter of Intent to advance India's cell and gene therapy ecosystem, supporting the development of domestic manufacturing capabilities and technology transfer.
- PioneerstrategicStrategic partnership unveiled at Victoria House, positioning collaboration in cell and gene therapy development and manufacturing capabilities.
- THSTI (Translational Health Science and Technological Institute)majorCollaboration to strengthen R&D in cell and gene therapy for cancer treatment, combining Miltenyi Biotec's technology platforms with THSTI's research capabilities to advance cell therapy development in India.
- Lino BiotechcoreMiltenyi Biotec acquired 100% of Lino Biotech, a Swiss biosensor company specializing in molecular interaction measurement. The acquisition aims to integrate the biosensor platform with Miltenyi's cell and gene therapy approaches to enhance quality control and reduce costs in bioprocessing and drug discovery.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Miltenyi Biotec competitors and assessment
Company assessmentBroad incumbents
- Merck KGaA (MilliporeSigma): Named peer in CGT tools and reagents, with deep overlap in bioprocessing consumables, cell culture media, and gene therapy manufacturing solutions through its Life Science division.
- Cytiva (Danaher): Named peer in CGT tools and reagents. Provides cell therapy manufacturing platforms, single-use bioprocessing, and instruments as part of Danaher's broader life-sciences portfolio.
- Thermo Fisher Scientific: Identified by Miltenyi as one of its top-5 peers in the global CGT tools and reagents market. Operates across instruments, reagents, and CDMO services with significantly greater scale.
- Lonza: Major CDMO and cell/gene therapy manufacturing solutions provider. Competes with Miltenyi in automated, closed-system cell processing and CGT process development.
- Charles River Laboratories: Provides research models, cell and gene therapy CRO/CDMO services, and bioprocessing solutions with overlapping CGT manufacturing capabilities.
- Beckman Coulter Life Sciences (Danaher): Part of Danaher's life-sciences portfolio; provides flow cytometry and cell-sorting instruments that compete with Miltenyi's MACS separation technology in research and clinical workflows.
Direct peers
- Sartorius: Co-vendor with Miltenyi in the German automated/closed cell therapy processing market. Directly competes in cell therapy bioprocessing equipment, bioreactors, and consumables.
- MaxCyte: Provides electroporation-based cell engineering and processing platforms used in CGT manufacturing. Competes with Miltenyi's CliniMACS Prodigy for cell therapy workflow integration.
- STEMCELL Technologies: Specialty reagents, media, and instruments for cell isolation, culture, and differentiation. Directly competes with Miltenyi's cell separation reagents and stem cell workflows.
- Bio-Techne: Provides reagents, proteins, and cell/gene therapy workflow tools. Competes with Miltenyi in research and process-development reagents for immunology and regenerative medicine.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Miltenyi Biotec social profiles
Digital presenceMiltenyi Biotec financial estimates
Financial estimateRevenue estimate
Valuation estimate
Miltenyi Biotec leadership team
Management profileNumber of profiles
Profiles4 records
Miltenyi Biotec subsidiaries and ownership
Company hierarchySubsidiaries1 record
Miltenyi Biotec funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Miltenyi Biotec M&A and investment
M&A and investmentM&A6 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Miltenyi Biotec
What does Miltenyi Biotec do?
Miltenyi Biotec designs, develops, manufactures, and integrates products that empower biomedical research and enable cell and gene therapy. The company sells automated closed-system cell therapy processing platforms (e.g., CliniMACS Prodigy), magnetic cell separation reagents and instruments, molecular interaction biosensors (via Lino Biotech), and a comprehensive portfolio of tools and reagents used in research, clinical, and commercial cell therapy manufacturing.
Is Miltenyi Biotec a public or private company?
Miltenyi Biotec is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Miltenyi Biotec founded?
Miltenyi Biotec was founded in 1989. It employs 1,001 to 5,000 people.
Where is Miltenyi Biotec based?
Miltenyi Biotec is headquartered in Bergisch Gladbach, Germany, in the Europe region.
How does Miltenyi Biotec make money?
Three revenue lines are on record. Cell and Gene Therapy Tools and Reagents are the primary driver. The others are automated Cell Therapy Processing Systems and cell Therapy Technologies.
Who are Miltenyi Biotec's main competitors?
Broad incumbents on record are Merck KGaA (MilliporeSigma), Cytiva (Danaher), Thermo Fisher Scientific, Lonza, Charles River Laboratories and Beckman Coulter Life Sciences (Danaher). Direct peers are Sartorius, MaxCyte, STEMCELL Technologies and Bio-Techne.
Does Miltenyi Biotec have an API?
No public API is recorded for Miltenyi Biotec.
What industry is Miltenyi Biotec in?
Miltenyi Biotec's product category is Cell and Gene Therapy Manufacturing Technologies. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 3345 and its SIC code is 2836.